View ValuationOcumetics Technology 将来の成長Future 基準チェック /06現在、 Ocumetics Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 01Ocumetics Technology Corp. announced that it expects to receive CAD 1.54 million in fundingOcumetics Technology Corp announced a private placement of up to 2,800,000 units of the Corporation at a price of CAD 0.55 per Unit for gross proceeds of up to CAD 1,540,000 on April 29, 2026. Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.75 for a period of three years from the date of issuance of the Warrant. The Corporation may pay finders fees to those who assist the Corporation in filling the Private Placement. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue.お知らせ • Dec 24Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026.お知らせ • Jul 10Ocumecs Technology Corp. Completes Staff Training for First-In-Human Clinical Study of Accommodaing Intraocular LensOcume cs Technology Corp. announced that it has completed training of the clinical team at its first study site in Mexico City. This training is in preparation for the upcoming first-in-human (FIH) clinical study of the Ocumetics accommodating intraocular lens. This training marks a critical milestone in Ocumetics' 18-year journey toward regulatory approval of a transformative accommodating intraocular lens technology intended to restore vision for patients undergoing cataract extraction. The training program is designed to ensure that all participating staff members are equipped with the specialized skills and knowledge necessary to implant the Ocumetics Lens with precision and safety. The Ocumetics Lens is designed to restore the ability to see both distant and near objects clearly without glasses following cataract surgery. The training program covers every phase of the clinical trial process, including pre-operative assessment, lens handling, surgical technique, and post-operative care. Using proven training methods, the curriculum ensures successful execution of the first clinical study of this novel technology. With clinical team training completed, and ethics committee approval pending, Ocumetics is poised to launch its historic FIH trial-an essential step toward clinical validation and eventual regulatory approval to market the Ocumetics Lens.お知らせ • Jun 05Ocumecs Technology Corp. Targets June 26, 2025 for Commencement of its First in Human StudyOcumetics Technology Corp. announced that it has set June 26, 2025 as the date for its first-in-human (FIH) clinical study. The FIH clinical study involves the implantation of the Company's inaugural accommodating intraocular lens (the "Ocumetics Lens") in the first group of study patients at a designated clinic in Mexico City. This milestone marks a historic moment for Ocumetics - culminating nearly two decades of relentless innovation, research, and development. For the first time in its 18-year history, Ocume cs will see its breakthrough accommodating intraocular lens implanted in human subjects, setting the stage for a new era in vision restoration. The Ocumetics Lens is designed to restore the eye's natural ability to shift focus from distance to near and back again, offering a potential paradigm shift in vision correction. The study will be conducted in collaboration with the Company's regulatory research consultants, whose expertise has been instrumental in ensuring readiness at the proposed site in Mexico City. The targeted FIH implantation date was set after consideration of lens manufacturing and testing procedures, study site preparation, staff training, regulatory application submission, and approval timelines. With this critical milestone in sight, Ocumetics moves one step closer to demonstrating the safety and performance of the Ocumetics Lens in a real-world clinical setting - laying the groundwork for future regulatory submissions and readiness for commercial distribution.お知らせ • Jun 04Ocumetics Technology Corp. announced that it expects to receive CAD 2.1 million in fundingOcumetics Technology Corp. announced a best efforts private placement that it will issue up to 6,000,000 units of the Corporation at an issue price of CAD 0.35 per unit for the gross proceeds of up to CAD 2,100,000 on June 4, 2025. Each Unit will consist of one common share in the share capital of the Corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.50 for a period of 24 months from the date of issuance of the Warrant. The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least CAD 0.60 per Common Share for a period of 30 consecutive trading days. The company will pay a cash commissions equal to 7% of the gross proceeds of the Offering received from investors introduced by Numus Capital to the Corporation and 4% of the gross proceeds of the Offering received from investors sourced by the Corporation. The Offering is expected to close in tranches. Common Shares, Warrants and Agent’s Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue.お知らせ • Jun 03Ocumetics Technology Corp. Announces Mexico City as Site for Its First in Human StudyOcumetics Technology Corp. announced that the first-in-human (FIH) clinical study for its revolutionary accommodating intraocular lens will take place in Mexico City. This follows a strategic decision to relocate the study from its originally planned site in the Dominican Republic that will allow Ocumetics to take advantage of resources that better meet the Company's needs. Preparations are currently underway to activate the clinical site in Mexico City, including staff training, regulatory submissions, and logistical planning. Ocumetics remains on track to begin human implantation of its novel accommodative intraocular lens in the summer of 2025.お知らせ • May 12Ocumecs Technology Corp. Announces Lens Design Freeze for First-In-Human StudyOcume cs Technology Corp. announced the successful completion of its optimized lens prototype design. With this milestone, Ocumetics has formally initiated a design freeze - locking in lens specifications that will be used in its upcoming first-in-human (FIH) clinical study planned for summer 2025. This decision follows a series of rigorous design optimizations, bench testing, and laboratory performance validations, including recent success in achieving the accommodative response necessary to proceed with first-in-human trials. The finalized prototype integrates Ocumetics' most advanced optical design, biomechanical engineering, and proprietary manufacturing methods, representing a new era in accommodative intraocular lens technology. The finalized design will now undergo final manufacturing scale-up and sterility validation procedures to prepare for clinical-grade production. The FIH study is a critical next step in Ocumetics' mission to provide a revolutionary solution for patients seeking freedom from glasses, contact lenses, and traditional intraocular implants.お知らせ • Mar 12Ocumetics Technology Corp. Appoints Michael Edwards to its Board of DirectorsOcumetics Technology Corp. announced that it has appointed Michael Edwards, BBA, CPA, CA, CLU, to its Board of Directors. Michael has an extensive background in accounting, taxation, corporate governance and fundraising in Canada. Michael graduated from Acadia University with a Bachelor of Business Administration and thereafter obtained his C.A. designation, achieving the highest provincial standing (PEI) on the Uniform Final Exams. Michael spent several years working for public accounting firms in increasing areas of responsibility, and completed the CICA In-Depth Tax Course. Michael was previously the Canadian Tax Manager for Michelin Tires Canada Ltd. and the Vice President, Finance for a regional residential/commercial real estate development company before returning to public accounting practice. Thereafter, he became a licensed life agent, obtained the Chartered Life Underwriter CLU designation, and currently holds a life brokers contract for several major life companies through Customized Insurance &Tax Solutions Inc. Currently, Michael is insurance life licensed and a registered Dealing Representative of Pinnacle Wealth Brokers Ltd. Michael specializes in insurance and exempt market investment products and is President and Director of EDC Tax Services Inc.お知らせ • Sep 10Ocumetics Technology Corp., Annual General Meeting, Nov 08, 2024Ocumetics Technology Corp., Annual General Meeting, Nov 08, 2024.お知らせ • May 17Ocumetics Technology Corp. announced that it expects to receive CAD 3.76 million in fundingOcumetics Technology Corp. announced a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to CAD 4,000,000 for gross proceeds of CAD 3,760,000 on May 15, 2024. The debentures will be subject to an original issue discount of 6%. The debentures will bear interest at rate of 18% per annum, compounded annually. The debentures will mature, and principal and interest will be payable by the corporation, on the date which is two years from the date of issue. The corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty. The principal will be convertible at the option of the holder into common shares of the corporation at a conversion price of CAD 0.32 per share. Interest will be convertible into common shares of the issuer pursuant to shares for debt applications, from time to time, at the option of the debenture holders. The debentures and the common shares issuable upon the conversion of the debentures will be subject to a four month hold period. The completion of the offering is subject to the final approval of the TSX Venture Exchange.お知らせ • Jan 17Ocumetics Technology Corp. announced that it has received CAD 0.4166 million in fundingOn January 17, 2024, Ocumetics Technology Corp. closed the transaction. The company issued 1,301,875 units at an issue price of CAD 0.32 per unit for gross proceeds of CAD 416,600. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.64 for a period of two years from the date of issuance of the warrant. The company paid finders fees to Leede Jones Gable Inc. consisting of cash commissions of CAD 200. All securities issued under the Private Placement are subject to a hold period of four months and one day.お知らせ • Dec 09Ocumetics Technology Corp. Announces Successful Completion of Animal Study in Preparation for Its First-In-Human Study, Anticipated to Commence in First Quarter of 2024 in the Dominican RepublicOcumetics Technology Corp. confirmed the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in first quarter of 2024 in the Dominican Republic. The biocompatibility of the Ocumetics accommodating intraocular lens (the "Ocumetics Accommodating Lens") was evaluated by surgical implantation of two lenses into the eyes of rabbits. The first lens, the Ocumetics Accommodating Lens, was compared to the second lens, a commercially available monofocal intraocular lens ("IOL") as a control. Results from this three-month animal study demonstrated that there were no biocompatibility or safety issues related to the Ocumetics Accommodating Lens when compared to the control IOL. The study also evaluated the occurrence of anterior and posterior capsular opacification in the rabbit model over the three month period. There were no significant differences between the two IOL groups in terms of posterior capsular opacification and anterior capsular opacification at the end of the study.お知らせ • Nov 17Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in fundingOcumetics Technology Corp. announced a non-brokered private placement of up to 3,125,000 units of at a price of CAD 0.32 per unit for gross proceeds of up to CAD 1,000,000 on November 15, 2023. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.64 for a period of two years from the date of issuance of the warrant. The company may pay finder’s fees on all or a portion of the private placement to eligible persons seeking subscribers to the financing, all in accordance with applicable securities laws and the policies of the TSX Venture Exchange.お知らせ • Sep 20Ocumetics Continues to Meet Significant Development Milestones Lens Design Optimized for Upcoming First in Human StudyOcumetics Technology Corp. confirms a remarkable achievement in the optimization of its vision correction technology - the Ocumetics Accommodating Lens. Through rigorous research and development efforts over the past two years, Ocumetics has modified its lens design five times, ultimately arriving at its final lens configuration version 10.5. Lens version 10.5 has been tested in vitro and in an animal model, and will be used in Ocumetics' upcoming human clinical trials. This achievement is a testament to Ocumetics' persistence and unwavering commitment to delivering the most advanced and efficient vision correction solution possible. The optimization process has been conducted with a meticulous focus on quality and performance, ensuring that the upcoming first-in-human study, anticipated to commence in First Quarter 2024 in the Dominican Republic, will benefit from the most advanced technology available.お知らせ • Jul 01Ocumetics Technology Corp., Annual General Meeting, Aug 25, 2023Ocumetics Technology Corp., Annual General Meeting, Aug 25, 2023.お知らせ • Jun 23Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in fundingOcumetics Technology Corp. announced a non-brokered private placement and will issue up to 3,333,333 units at an issue price of CAD 0.3 per common share for gross proceeds of up to CAD 999,999.9 on June 22, 2023. Each unit will consist of one common share in the share capital of the corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.6 for a period of two years from the date of issuance of the warrant. There will be no minimum subscription level for this offering. In the event that aggregate subscriptions for units under the offering exceed the maximum number of securities to be distributed, then units will be sold to qualifying subscribers on a pro rata basis based on the number of units subscribed for. Insiders may participate in the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after closing of the offering. The offering may include finder’s fees commission’s payable in cash and/or securities and is subject to approval of the TSX Venture Exchange.お知らせ • Jun 13+ 1 more updateOcumetics Technology Corp. Announces Executive ChangesOcumetics Technology Corp. announced that it has appointed Mr. Dean Burns as Ocumetics' President and CEO. Mr. Burns will also join the Ocumetics board of directors. Mr. Burns was previously a consultant of the Corporation, assisting with the Corporation's regulatory and marketing endeavours. Further to the announcement of Dr. Mark Lee's resignation effective June 30, 2023, Dr. Lee stepped down as President and CEO on June 12, 2023. Mr. Burns is recently retired from Alcon Vision, where he was a Senior Director of Cataract Instrumentation and Advanced Consumable Technology, a USD 750 million business of Alcon. At Alcon, Mr. Burns managed technologies in four therapeutic categories: Cataract, Refractive, Retinal and Pharmaceutical. Mr. Burns' 27-year career with Alcon brings a diverse healthcare experience to Ocumetics. His experience included developing plans to commercialize acquired technologies and line extension of existing products. He also has skills and experience in marketing and sales management, manufacturing, comprehensive understanding of the regulatory process for devices, Key Opinion Leader management, and surgeon clinical training. Mr. Burns' accomplishments include over 15 FDA product approvals and five business development and licensing acquisition projects totaling USD 2.3 billion.お知らせ • Feb 15Ocumetics Technology Corp. Announces Successful Completion of Animal StudiesOcumetics Technology Corp. announced the successful completion of its latest animal studies. The lens design met and exceeded its expectations. This is the first in a series of biocompatibility studies, the second of which is scheduled to commence in March 2023. The biocompatibility studies will take 3 months to complete, which means it should be able to begin first-in-human proof of concept studies in July or August of 2023.お知らせ • Feb 02Ocumetics Technology Corp. announced that it has received CAD 0.672108 million in fundingOcumetics Technology Corp. announced the closing of a non-brokered private placement of 1,493,574 units at a price of CAD 0.45 per unit for gross proceeds of CAD 672,108.15 on February 1, 2023. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.90 for a period of two years from the date of issuance of the warrant. The company may paid finder’s fees of CAD 4,185 in accordance with applicable securities laws and the policies of the TSX Venture Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period expiring four months and one day. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ocumetics Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:OTCF.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025N/A-5-3-3N/A9/30/2025N/A-4-2-2N/A6/30/2025N/A-4-2-2N/A3/31/2025N/A-3-3-3N/A12/31/2024N/A-3-3-2N/A9/30/2024N/A-3-2-2N/A6/30/2024N/A-3-3-2N/A3/31/2024N/A-4-2-2N/A12/31/2023N/A-4-2-2N/A9/30/2023N/A-3-2-2N/A6/30/2023N/A-3-2-2N/A3/31/2023N/A-2-2-2N/A12/31/2022N/A-2-2-2N/A12/31/2021N/A-4-3-2N/A7/31/2021N/A-100N/A4/30/2021N/A000N/A7/31/2020N/A000N/A7/31/2019N/A0N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: OTCF.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OTCF.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OTCF.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OTCF.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OTCF.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OTCF.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 09:16終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ocumetics Technology Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 01Ocumetics Technology Corp. announced that it expects to receive CAD 1.54 million in fundingOcumetics Technology Corp announced a private placement of up to 2,800,000 units of the Corporation at a price of CAD 0.55 per Unit for gross proceeds of up to CAD 1,540,000 on April 29, 2026. Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.75 for a period of three years from the date of issuance of the Warrant. The Corporation may pay finders fees to those who assist the Corporation in filling the Private Placement. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue.
お知らせ • Dec 24Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026.
お知らせ • Jul 10Ocumecs Technology Corp. Completes Staff Training for First-In-Human Clinical Study of Accommodaing Intraocular LensOcume cs Technology Corp. announced that it has completed training of the clinical team at its first study site in Mexico City. This training is in preparation for the upcoming first-in-human (FIH) clinical study of the Ocumetics accommodating intraocular lens. This training marks a critical milestone in Ocumetics' 18-year journey toward regulatory approval of a transformative accommodating intraocular lens technology intended to restore vision for patients undergoing cataract extraction. The training program is designed to ensure that all participating staff members are equipped with the specialized skills and knowledge necessary to implant the Ocumetics Lens with precision and safety. The Ocumetics Lens is designed to restore the ability to see both distant and near objects clearly without glasses following cataract surgery. The training program covers every phase of the clinical trial process, including pre-operative assessment, lens handling, surgical technique, and post-operative care. Using proven training methods, the curriculum ensures successful execution of the first clinical study of this novel technology. With clinical team training completed, and ethics committee approval pending, Ocumetics is poised to launch its historic FIH trial-an essential step toward clinical validation and eventual regulatory approval to market the Ocumetics Lens.
お知らせ • Jun 05Ocumecs Technology Corp. Targets June 26, 2025 for Commencement of its First in Human StudyOcumetics Technology Corp. announced that it has set June 26, 2025 as the date for its first-in-human (FIH) clinical study. The FIH clinical study involves the implantation of the Company's inaugural accommodating intraocular lens (the "Ocumetics Lens") in the first group of study patients at a designated clinic in Mexico City. This milestone marks a historic moment for Ocumetics - culminating nearly two decades of relentless innovation, research, and development. For the first time in its 18-year history, Ocume cs will see its breakthrough accommodating intraocular lens implanted in human subjects, setting the stage for a new era in vision restoration. The Ocumetics Lens is designed to restore the eye's natural ability to shift focus from distance to near and back again, offering a potential paradigm shift in vision correction. The study will be conducted in collaboration with the Company's regulatory research consultants, whose expertise has been instrumental in ensuring readiness at the proposed site in Mexico City. The targeted FIH implantation date was set after consideration of lens manufacturing and testing procedures, study site preparation, staff training, regulatory application submission, and approval timelines. With this critical milestone in sight, Ocumetics moves one step closer to demonstrating the safety and performance of the Ocumetics Lens in a real-world clinical setting - laying the groundwork for future regulatory submissions and readiness for commercial distribution.
お知らせ • Jun 04Ocumetics Technology Corp. announced that it expects to receive CAD 2.1 million in fundingOcumetics Technology Corp. announced a best efforts private placement that it will issue up to 6,000,000 units of the Corporation at an issue price of CAD 0.35 per unit for the gross proceeds of up to CAD 2,100,000 on June 4, 2025. Each Unit will consist of one common share in the share capital of the Corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.50 for a period of 24 months from the date of issuance of the Warrant. The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least CAD 0.60 per Common Share for a period of 30 consecutive trading days. The company will pay a cash commissions equal to 7% of the gross proceeds of the Offering received from investors introduced by Numus Capital to the Corporation and 4% of the gross proceeds of the Offering received from investors sourced by the Corporation. The Offering is expected to close in tranches. Common Shares, Warrants and Agent’s Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue.
お知らせ • Jun 03Ocumetics Technology Corp. Announces Mexico City as Site for Its First in Human StudyOcumetics Technology Corp. announced that the first-in-human (FIH) clinical study for its revolutionary accommodating intraocular lens will take place in Mexico City. This follows a strategic decision to relocate the study from its originally planned site in the Dominican Republic that will allow Ocumetics to take advantage of resources that better meet the Company's needs. Preparations are currently underway to activate the clinical site in Mexico City, including staff training, regulatory submissions, and logistical planning. Ocumetics remains on track to begin human implantation of its novel accommodative intraocular lens in the summer of 2025.
お知らせ • May 12Ocumecs Technology Corp. Announces Lens Design Freeze for First-In-Human StudyOcume cs Technology Corp. announced the successful completion of its optimized lens prototype design. With this milestone, Ocumetics has formally initiated a design freeze - locking in lens specifications that will be used in its upcoming first-in-human (FIH) clinical study planned for summer 2025. This decision follows a series of rigorous design optimizations, bench testing, and laboratory performance validations, including recent success in achieving the accommodative response necessary to proceed with first-in-human trials. The finalized prototype integrates Ocumetics' most advanced optical design, biomechanical engineering, and proprietary manufacturing methods, representing a new era in accommodative intraocular lens technology. The finalized design will now undergo final manufacturing scale-up and sterility validation procedures to prepare for clinical-grade production. The FIH study is a critical next step in Ocumetics' mission to provide a revolutionary solution for patients seeking freedom from glasses, contact lenses, and traditional intraocular implants.
お知らせ • Mar 12Ocumetics Technology Corp. Appoints Michael Edwards to its Board of DirectorsOcumetics Technology Corp. announced that it has appointed Michael Edwards, BBA, CPA, CA, CLU, to its Board of Directors. Michael has an extensive background in accounting, taxation, corporate governance and fundraising in Canada. Michael graduated from Acadia University with a Bachelor of Business Administration and thereafter obtained his C.A. designation, achieving the highest provincial standing (PEI) on the Uniform Final Exams. Michael spent several years working for public accounting firms in increasing areas of responsibility, and completed the CICA In-Depth Tax Course. Michael was previously the Canadian Tax Manager for Michelin Tires Canada Ltd. and the Vice President, Finance for a regional residential/commercial real estate development company before returning to public accounting practice. Thereafter, he became a licensed life agent, obtained the Chartered Life Underwriter CLU designation, and currently holds a life brokers contract for several major life companies through Customized Insurance &Tax Solutions Inc. Currently, Michael is insurance life licensed and a registered Dealing Representative of Pinnacle Wealth Brokers Ltd. Michael specializes in insurance and exempt market investment products and is President and Director of EDC Tax Services Inc.
お知らせ • Sep 10Ocumetics Technology Corp., Annual General Meeting, Nov 08, 2024Ocumetics Technology Corp., Annual General Meeting, Nov 08, 2024.
お知らせ • May 17Ocumetics Technology Corp. announced that it expects to receive CAD 3.76 million in fundingOcumetics Technology Corp. announced a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to CAD 4,000,000 for gross proceeds of CAD 3,760,000 on May 15, 2024. The debentures will be subject to an original issue discount of 6%. The debentures will bear interest at rate of 18% per annum, compounded annually. The debentures will mature, and principal and interest will be payable by the corporation, on the date which is two years from the date of issue. The corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty. The principal will be convertible at the option of the holder into common shares of the corporation at a conversion price of CAD 0.32 per share. Interest will be convertible into common shares of the issuer pursuant to shares for debt applications, from time to time, at the option of the debenture holders. The debentures and the common shares issuable upon the conversion of the debentures will be subject to a four month hold period. The completion of the offering is subject to the final approval of the TSX Venture Exchange.
お知らせ • Jan 17Ocumetics Technology Corp. announced that it has received CAD 0.4166 million in fundingOn January 17, 2024, Ocumetics Technology Corp. closed the transaction. The company issued 1,301,875 units at an issue price of CAD 0.32 per unit for gross proceeds of CAD 416,600. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.64 for a period of two years from the date of issuance of the warrant. The company paid finders fees to Leede Jones Gable Inc. consisting of cash commissions of CAD 200. All securities issued under the Private Placement are subject to a hold period of four months and one day.
お知らせ • Dec 09Ocumetics Technology Corp. Announces Successful Completion of Animal Study in Preparation for Its First-In-Human Study, Anticipated to Commence in First Quarter of 2024 in the Dominican RepublicOcumetics Technology Corp. confirmed the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in first quarter of 2024 in the Dominican Republic. The biocompatibility of the Ocumetics accommodating intraocular lens (the "Ocumetics Accommodating Lens") was evaluated by surgical implantation of two lenses into the eyes of rabbits. The first lens, the Ocumetics Accommodating Lens, was compared to the second lens, a commercially available monofocal intraocular lens ("IOL") as a control. Results from this three-month animal study demonstrated that there were no biocompatibility or safety issues related to the Ocumetics Accommodating Lens when compared to the control IOL. The study also evaluated the occurrence of anterior and posterior capsular opacification in the rabbit model over the three month period. There were no significant differences between the two IOL groups in terms of posterior capsular opacification and anterior capsular opacification at the end of the study.
お知らせ • Nov 17Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in fundingOcumetics Technology Corp. announced a non-brokered private placement of up to 3,125,000 units of at a price of CAD 0.32 per unit for gross proceeds of up to CAD 1,000,000 on November 15, 2023. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.64 for a period of two years from the date of issuance of the warrant. The company may pay finder’s fees on all or a portion of the private placement to eligible persons seeking subscribers to the financing, all in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
お知らせ • Sep 20Ocumetics Continues to Meet Significant Development Milestones Lens Design Optimized for Upcoming First in Human StudyOcumetics Technology Corp. confirms a remarkable achievement in the optimization of its vision correction technology - the Ocumetics Accommodating Lens. Through rigorous research and development efforts over the past two years, Ocumetics has modified its lens design five times, ultimately arriving at its final lens configuration version 10.5. Lens version 10.5 has been tested in vitro and in an animal model, and will be used in Ocumetics' upcoming human clinical trials. This achievement is a testament to Ocumetics' persistence and unwavering commitment to delivering the most advanced and efficient vision correction solution possible. The optimization process has been conducted with a meticulous focus on quality and performance, ensuring that the upcoming first-in-human study, anticipated to commence in First Quarter 2024 in the Dominican Republic, will benefit from the most advanced technology available.
お知らせ • Jul 01Ocumetics Technology Corp., Annual General Meeting, Aug 25, 2023Ocumetics Technology Corp., Annual General Meeting, Aug 25, 2023.
お知らせ • Jun 23Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in fundingOcumetics Technology Corp. announced a non-brokered private placement and will issue up to 3,333,333 units at an issue price of CAD 0.3 per common share for gross proceeds of up to CAD 999,999.9 on June 22, 2023. Each unit will consist of one common share in the share capital of the corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.6 for a period of two years from the date of issuance of the warrant. There will be no minimum subscription level for this offering. In the event that aggregate subscriptions for units under the offering exceed the maximum number of securities to be distributed, then units will be sold to qualifying subscribers on a pro rata basis based on the number of units subscribed for. Insiders may participate in the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after closing of the offering. The offering may include finder’s fees commission’s payable in cash and/or securities and is subject to approval of the TSX Venture Exchange.
お知らせ • Jun 13+ 1 more updateOcumetics Technology Corp. Announces Executive ChangesOcumetics Technology Corp. announced that it has appointed Mr. Dean Burns as Ocumetics' President and CEO. Mr. Burns will also join the Ocumetics board of directors. Mr. Burns was previously a consultant of the Corporation, assisting with the Corporation's regulatory and marketing endeavours. Further to the announcement of Dr. Mark Lee's resignation effective June 30, 2023, Dr. Lee stepped down as President and CEO on June 12, 2023. Mr. Burns is recently retired from Alcon Vision, where he was a Senior Director of Cataract Instrumentation and Advanced Consumable Technology, a USD 750 million business of Alcon. At Alcon, Mr. Burns managed technologies in four therapeutic categories: Cataract, Refractive, Retinal and Pharmaceutical. Mr. Burns' 27-year career with Alcon brings a diverse healthcare experience to Ocumetics. His experience included developing plans to commercialize acquired technologies and line extension of existing products. He also has skills and experience in marketing and sales management, manufacturing, comprehensive understanding of the regulatory process for devices, Key Opinion Leader management, and surgeon clinical training. Mr. Burns' accomplishments include over 15 FDA product approvals and five business development and licensing acquisition projects totaling USD 2.3 billion.
お知らせ • Feb 15Ocumetics Technology Corp. Announces Successful Completion of Animal StudiesOcumetics Technology Corp. announced the successful completion of its latest animal studies. The lens design met and exceeded its expectations. This is the first in a series of biocompatibility studies, the second of which is scheduled to commence in March 2023. The biocompatibility studies will take 3 months to complete, which means it should be able to begin first-in-human proof of concept studies in July or August of 2023.
お知らせ • Feb 02Ocumetics Technology Corp. announced that it has received CAD 0.672108 million in fundingOcumetics Technology Corp. announced the closing of a non-brokered private placement of 1,493,574 units at a price of CAD 0.45 per unit for gross proceeds of CAD 672,108.15 on February 1, 2023. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.90 for a period of two years from the date of issuance of the warrant. The company may paid finder’s fees of CAD 4,185 in accordance with applicable securities laws and the policies of the TSX Venture Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period expiring four months and one day.